Wang H - Search Results

1

Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.

Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, Zhang R. Wang H, et al. Int J Oncol. 2002 Jul;21(1):73-80. Int J Oncol. 2002. PMID: 12063552

2

Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.

Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R. Wang H, et al. Among authors: wang s. Int J Oncol. 2002 Apr;20(4):745-52. Int J Oncol. 2002. PMID: 11894120

3

Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.

Prasad G, Wang H, Agrawal S, Zhang R. Prasad G, et al. Among authors: wang h. Anticancer Res. 2002 Jan-Feb;22(1A):107-16. Anticancer Res. 2002. PMID: 12017271

4

Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.

Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R. Wang H, et al. Mol Med. 2002 Apr;8(4):185-99. Mol Med. 2002. PMID: 12149568 Free PMC article.

5

Antisense oligonucleotides targeting RI alpha subunit of protein kinase A. In vitro and in vivo anti-tumor activity and pharmacokinetics.

Zhang R, Wang H. Zhang R, et al. Among authors: wang h. Methods Mol Med. 2003;75:637-54. Methods Mol Med. 2003. PMID: 12407769 No abstract available.

6

Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.

Wang H, Yu D, Agrawal S, Zhang R. Wang H, et al. Prostate. 2003 Feb 15;54(3):194-205. doi: 10.1002/pros.10187. Prostate. 2003. PMID: 12518324

7

Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.

Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R. Wang H, et al. Ann N Y Acad Sci. 2003 Dec;1002:217-35. doi: 10.1196/annals.1281.025. Ann N Y Acad Sci. 2003. PMID: 14751837

8

Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.

Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner JA, Agrawal S, Zhang R. Zhang Z, et al. Among authors: wang h. Clin Cancer Res. 2004 Feb 15;10(4):1263-73. doi: 10.1158/1078-0432.ccr-0245-03. Clin Cancer Res. 2004. PMID: 14977824

9

Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy.

Wang H, Li M, Rinehart JJ, Zhang R. Wang H, et al. Clin Cancer Res. 2004 Mar 1;10(5):1633-44. doi: 10.1158/1078-0432.ccr-0829-3. Clin Cancer Res. 2004. PMID: 15014014

10

Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.

Zhang R, Wang H, Agrawal S. Zhang R, et al. Among authors: wang h. Curr Cancer Drug Targets. 2005 Feb;5(1):43-9. doi: 10.2174/1568009053332663. Curr Cancer Drug Targets. 2005. PMID: 15720188 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

148,594 results

Search Page

Filters